2.34
+0.15(+6.85%)
Currency In USD
| Previous Close | 2.19 |
| Open | 2.19 |
| Day High | 2.37 |
| Day Low | 2.15 |
| 52-Week High | 3 |
| 52-Week Low | 1.26 |
| Volume | 59,347 |
| Average Volume | 223,039 |
| Market Cap | 65.23M |
| PE | -3.39 |
| EPS | -0.69 |
| Moving Average 50 Days | 2.13 |
| Moving Average 200 Days | 1.9 |
| Change | 0.15 |
If you invested $1000 in Immix Biopharma, Inc. (IMMX) since IPO date, it would be worth $637.6 as of July 02, 2025 at a share price of $2.34. Whereas If you bought $1000 worth of Immix Biopharma, Inc. (IMMX) shares 3 years ago, it would be worth $936 as of July 02, 2025 at a share price of $2.34.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Immix Biopharma Attends FDA CEO Forum in Washington DC
GlobeNewswire Inc.
Jun 06, 2025 1:39 PM GMT
– Selected to Attend In-Person Event on June 5 led by FDA Commissioner Marty A. Makary, M.D., M.P.H. – LOS ANGELES, CA, June 06, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopha
Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
GlobeNewswire Inc.
Jun 03, 2025 6:55 PM GMT
Immix Biopharma today presented results at ASCO from its U.S. multi-center NEXICART-2 Phase 1/2 clinical trial of NXC-201, meeting its primary endpoint. – NXC-201 met primary endpoint with a complete response (CR) rate of 70% (7/10 patients) – – No
Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
GlobeNewswire Inc.
May 23, 2025 1:05 PM GMT
– Patient enrollment exceeding expectations – – 14 U.S. sites actively enrolling; 10 U.S. sites added since last update – – Anticipate completing NEXICART-2 clinical trial ahead of schedule – LOS ANGELES, CA, May 23, 2025 (GLOBE NEWSWIRE) -- Immix